Avalo Therapeutics, Inc.
AVTXHealthcare|Biotechnology|US
$6.93
+0.30 (+4.52%)
DCF Value
$0.99
Tangible Book / Share
$7.74
Cash / Share
$7.14
Ownership Breakdown
89.6%
Float
53.6M
Shares Outstanding
48.1M
Float Shares
Major Holders (40)
Combined: 241.6%
Holders of 5%+ from their latest Schedule 13D/13G filing in the last two years. Percentages are as of each filing date.
| Holder | Type | % of Class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Commodore Capital LP | IA, PN | 9.90% | 5,721,109 | Jun 18, 2026 | 13D/G |
| Robert Egen Atkinson | HC, IN | 9.90% | 5,721,109 | Jun 18, 2026 | 13D/G |
| Michael Kramarz | HC, IN | 9.90% | 5,721,109 | Jun 18, 2026 | 13D/G |
| Commodore Capital Master LP | Partnership | 9.90% | 5,721,109 | Jun 18, 2026 | 13D/G |
| TCG Crossover Fund II, L.P. | Partnership | 7.90% | 3,017,120 | May 12, 2026 | 13D/G |
| Chen Yu | Individual | 7.90% | 3,017,120 | May 12, 2026 | 13D/G |
| TCG Crossover GP II, LLC | Other | 7.90% | 3,017,120 | May 12, 2026 | 13D/G |
| Affinity Healthcare Fund, LP | Partnership | 7.65% | 1,006,217 | Nov 13, 2025 | 13D/G |
| David Kroin | HC, IN | 6.87% | 3,610,000 | Aug 14, 2026 | 13D/G |
| Deep Track Capital, LP | IA, OO | 6.87% | 3,610,000 | Aug 14, 2026 | 13D/G |
| Deep Track Biotechnology Master Fund, Ltd. | Corporation | 6.87% | 3,610,000 | Aug 14, 2026 | 13D/G |
| BlackRock, Inc. | Holding company | 6.50% | 3,415,731 | Jul 27, 2026 | 13D/G |
| RA Capital Management, L.P. | IA, PN | 6.30% | 3,483,099 | Aug 14, 2026 | 13D/G |
| Peter Kolchinsky | HC, IN | 6.30% | 3,483,099 | Aug 14, 2026 | 13D/G |
| Rajeev Shah | HC, IN | 6.30% | 3,483,099 | Aug 14, 2026 | 13D/G |
| RA Capital Healthcare Fund, L.P. | Partnership | 6.30% | 3,483,099 | Aug 14, 2026 | 13D/G |
| OrbiMed Capital GP IX LLC | Other | 6.00% | 644,667 | Aug 14, 2025 | 13D/G |
| David Johnson | HC, IN | 5.90% | 3,163,866 | Aug 14, 2026 | 13D/G |
| Caligan Partners LP | IA, PN | 5.90% | 3,163,866 | Aug 14, 2026 | 13D/G |
| Michael Cho | HC, IN | 5.50% | 2,900,000 | Aug 13, 2026 | 13D/G |
| Affinity Asset Advisors, LLC | IA, OO | 5.50% | 2,900,000 | Aug 13, 2026 | 13D/G |
| State Street Corporation | Holding company | 5.50% | 2,889,287 | Aug 7, 2026 | 13D/G |
| BVF Partners L P/Il | IA, PN | 5.30% | 2,801,545 | Aug 14, 2026 | 13D/G |
| BVF Inc/Il | Corporation | 5.30% | 2,801,545 | Aug 14, 2026 | 13D/G |
| Lampert Mark N | Individual | 5.30% | 2,801,545 | Aug 14, 2026 | 13D/G |
| Trails Edge Capital Partners, LP | IA, PN | 5.20% | 2,803,761 | Oct 29, 2026 | 13D/G |
| Trails Edge Biotechnology Master Fund, LP | Partnership | 5.20% | 2,803,761 | Oct 29, 2026 | 13D/G |
| Ortav Yehudai | Individual | 5.20% | 2,803,761 | Oct 29, 2026 | 13D/G |
| Point72 Capital Advisors, Inc. | Corporation | 5.20% | 2,710,817 | May 26, 2026 | 13D/G |
| Point72 Asset Management, L.P. | Partnership | 5.20% | 2,710,817 | May 26, 2026 | 13D/G |
| Steven A. Cohen | Individual | 5.20% | 2,710,817 | May 26, 2026 | 13D/G |
| BVF GP Holdings LLC | Other | 4.80% | 2,574,007 | Aug 14, 2026 | 13D/G |
| Avoro Capital Advisors LLC | IA, OO | 4.44% | 2,333,333 | Aug 14, 2026 | 13D/G |
| Behzad Aghazadeh | HC, IN | 4.44% | 2,333,333 | Aug 14, 2026 | 13D/G |
| The Vanguard Group | Investment adviser | 4.43% | 804,084 | Jan 30, 2026 | 13D/G |
| Patrick J. Crutcher | Individual | 4.20% | 549,467 | Aug 27, 2025 | 13D/G |
| Ikarian Capital, LLC | Investment adviser | 3.80% | 711,967 | Nov 14, 2025 | 13D/G |
| Neil Shahrestani | HC, IN | 3.80% | 711,967 | Nov 14, 2025 | 13D/G |
| Nantahala Capital Management, LLC | Investment adviser | 3.54% | 1,862,250 | Aug 14, 2026 | 13D/G |
| Wilmot B. Harkey | Holding company | 3.54% | 1,862,250 | Aug 14, 2026 | 13D/G |
Insider Trades (100)
Last 4 quarters: 2,003,849 acquired · 973,109 disposed
| Insider | Position | Date | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jain Rita | director | Sep 30, 2026 | AWARD | 1,322 | $15.33 | $20.3K | Form 4 |
| Lind Kevin Robert | director | Sep 30, 2026 | AWARD | 1,352 | $15.33 | $20.7K | Form 4 |
| Philip Ron M | director | Sep 30, 2026 | AWARD | 1,109 | $15.33 | $17.0K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | Sep 16, 2026 | OPTION EX. | 12,394 | $9.88 | $122.5K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | Sep 16, 2026 | OPTION EX. | 12,394 | $9.88 | $122.5K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | Sep 16, 2026 | SELL | 12,394 | $16.33 | $202.4K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | Sep 10, 2026 | OPTION EX. | 10,185 | $8.04 | $81.9K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | Sep 10, 2026 | OPTION EX. | 10,185 | $8.04 | $81.9K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | Sep 10, 2026 | SELL | 10,185 | $17.62 | $179.5K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Aug 28, 2026 | OPTION EX. | 679 | $8.04 | $5.5K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Aug 28, 2026 | OPTION EX. | 679 | $8.04 | $5.5K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Aug 28, 2026 | SELL | 679 | $20.00 | $13.6K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | Aug 17, 2026 | OPTION EX. | 37,945 | $9.88 | $374.9K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | Aug 17, 2026 | OPTION EX. | 2,876 | $9.88 | $28.4K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | Aug 18, 2026 | OPTION EX. | 31,031 | $9.88 | $306.6K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | Aug 17, 2026 | OPTION EX. | 2,876 | $9.88 | $28.4K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | Aug 17, 2026 | OPTION EX. | 37,945 | $9.88 | $374.9K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | Aug 18, 2026 | OPTION EX. | 31,031 | $9.88 | $306.6K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | Aug 17, 2026 | SELL | 37,945 | $19.85 | $753.3K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | Aug 17, 2026 | SELL | 3,749 | $19.94 | $74.8K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | Aug 18, 2026 | SELL | 31,031 | $20.05 | $622.3K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Aug 17, 2026 | OPTION EX. | 1,000 | $12.65 | $12.7K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Aug 17, 2026 | OPTION EX. | 1,000 | $12.65 | $12.7K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Aug 17, 2026 | SELL | 1,000 | $20.00 | $20.0K | Form 4 |
| Riley Jennifer | Chief Strategy Officer | Aug 11, 2026 | SELL | 2,655 | $19.59 | $52.0K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Aug 10, 2026 | OPTION EX. | 679 | $8.04 | $5.5K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Aug 10, 2026 | OPTION EX. | 679 | $8.04 | $5.5K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Aug 10, 2026 | SELL | 679 | $20.00 | $13.6K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Jul 27, 2026 | OPTION EX. | 1,000 | $12.65 | $12.7K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Jul 27, 2026 | OPTION EX. | 1,000 | $12.65 | $12.7K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Jul 27, 2026 | SELL | 1,000 | $20.00 | $20.0K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Jun 30, 2026 | OPTION EX. | 2,875 | $12.65 | $36.4K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Jun 30, 2026 | OPTION EX. | 1,779 | $8.04 | $14.3K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Jun 30, 2026 | OPTION EX. | 1,779 | $8.04 | $14.3K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Jun 30, 2026 | OPTION EX. | 2,875 | $12.65 | $36.4K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Jun 30, 2026 | SELL | 4,654 | $20.00 | $93.1K | Form 4 |
| Philip Ron M | director | Jun 30, 2026 | AWARD | 69 | $18.48 | $1.3K | Form 4 |
| Lind Kevin Robert | director | Jun 30, 2026 | AWARD | 1,105 | $18.48 | $20.4K | Form 4 |
| Jain Rita | director | Jun 30, 2026 | AWARD | 1,080 | $18.48 | $20.0K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Jun 23, 2026 | OPTION EX. | 1,450 | $8.04 | $11.7K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Jun 23, 2026 | OPTION EX. | 1,450 | $8.04 | $11.7K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Jun 23, 2026 | SELL | 1,450 | $18.00 | $26.1K | Form 4 |
| Philip Ron M | director | Jun 23, 2026 | AWARD | 40,200 | $17.83 | $716.8K | Form 4 |
| Philip Ron M | Jun 23, 2026 | OTHER | 0 | — | — | Form 4 | |
| Riley Jennifer | Chief Strategy Officer | Jun 10, 2026 | TAX W/H | 588 | $13.10 | $7.7K | Form 4 |
| VARKI PAUL | Chief Legal Officer | Jun 10, 2026 | TAX W/H | 1,081 | $13.10 | $14.2K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | Jun 10, 2026 | TAX W/H | 138 | $13.10 | $1.8K | Form 4 |
| Doyle Mittie | Chief Medical Officer | Jun 10, 2026 | TAX W/H | 1,084 | $13.10 | $14.2K | Form 4 |
| Lind Kevin Robert | director | Jun 2, 2026 | AWARD | 20,100 | $13.96 | $280.6K | Form 4 |
| Truex Samantha | director | Jun 2, 2026 | AWARD | 20,100 | $13.96 | $280.6K | Form 4 |
| KAPLAN GILLA | director | Jun 2, 2026 | AWARD | 20,100 | $13.96 | $280.6K | Form 4 |
| KANTOFF AARON | director | Jun 2, 2026 | AWARD | 20,100 | $13.96 | $280.6K | Form 4 |
| Heffernan Michael Thomas | director | Jun 2, 2026 | AWARD | 29,500 | $13.96 | $411.8K | Form 4 |
| Jain Rita | director | Jun 2, 2026 | AWARD | 20,100 | $13.96 | $280.6K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 28, 2026 | OPTION EX. | 679 | $8.04 | $5.5K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 28, 2026 | OPTION EX. | 679 | $8.04 | $5.5K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 28, 2026 | SELL | 679 | $16.00 | $10.9K | Form 4 |
| Riley Jennifer | Chief Strategy Officer | May 21, 2026 | AWARD | 34,200 | — | — | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | May 21, 2026 | AWARD | 39,900 | — | — | Form 4 |
| VARKI PAUL | Chief Legal Officer | May 21, 2026 | AWARD | 24,300 | — | — | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 21, 2026 | AWARD | 43,500 | — | — | Form 4 |
| NEIL GARRY ARTHUR | director, officer: Chief Executive Officer | May 21, 2026 | AWARD | 100,200 | — | — | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 15, 2026 | OPTION EX. | 3,000 | $12.65 | $38.0K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 15, 2026 | OPTION EX. | 3,000 | $12.65 | $38.0K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 15, 2026 | SELL | 3,000 | $18.76 | $56.3K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | May 7, 2026 | OPTION EX. | 18,606 | $9.88 | $183.8K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | May 7, 2026 | OPTION EX. | 18,606 | $9.88 | $183.8K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | May 7, 2026 | SELL | 18,606 | $24.12 | $448.8K | Form 4 |
| VARKI PAUL | Chief Legal Officer | May 6, 2026 | OPTION EX. | 62,500 | $13.43 | $839.4K | Form 4 |
| VARKI PAUL | Chief Legal Officer | May 6, 2026 | OPTION EX. | 12,563 | $8.04 | $101.0K | Form 4 |
| VARKI PAUL | Chief Legal Officer | May 6, 2026 | OPTION EX. | 12,563 | $8.04 | $101.0K | Form 4 |
| VARKI PAUL | Chief Legal Officer | May 6, 2026 | OPTION EX. | 62,500 | $13.43 | $839.4K | Form 4 |
| VARKI PAUL | Chief Legal Officer | May 6, 2026 | SELL | 37,375 | $18.91 | $706.8K | Form 4 |
| VARKI PAUL | Chief Legal Officer | May 6, 2026 | SELL | 5,196 | $19.78 | $102.8K | Form 4 |
| VARKI PAUL | Chief Legal Officer | May 6, 2026 | SELL | 22,839 | $21.22 | $484.5K | Form 4 |
| VARKI PAUL | Chief Legal Officer | May 6, 2026 | SELL | 9,253 | $22.70 | $210.0K | Form 4 |
| VARKI PAUL | Chief Legal Officer | May 6, 2026 | SELL | 400 | $23.71 | $9.5K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | May 6, 2026 | OPTION EX. | 47,000 | $8.04 | $377.9K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | May 6, 2026 | OPTION EX. | 47,000 | $8.04 | $377.9K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | May 6, 2026 | SELL | 13,834 | $18.55 | $256.7K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | May 6, 2026 | SELL | 12,347 | $19.28 | $238.1K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | May 6, 2026 | SELL | 2,700 | $20.76 | $56.1K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | May 6, 2026 | SELL | 9,219 | $21.37 | $197.0K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | May 6, 2026 | SELL | 8,900 | $22.57 | $200.9K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 5, 2026 | OPTION EX. | 1,000 | $12.65 | $12.7K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 5, 2026 | OPTION EX. | 679 | $8.04 | $5.5K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 6, 2026 | OPTION EX. | 77,905 | $12.65 | $985.5K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 6, 2026 | OPTION EX. | 28,650 | $8.04 | $230.3K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 6, 2026 | OPTION EX. | 28,650 | $8.04 | $230.3K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 6, 2026 | SELL | 27,538 | $18.03 | $496.4K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 6, 2026 | OPTION EX. | 77,905 | $12.65 | $985.5K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 6, 2026 | SELL | 5,000 | $19.65 | $98.3K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 6, 2026 | SELL | 44,944 | $21.20 | $952.7K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 6, 2026 | SELL | 19,015 | $22.41 | $426.1K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 5, 2026 | OPTION EX. | 679 | $8.04 | $5.5K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 5, 2026 | OPTION EX. | 1,000 | $12.65 | $12.7K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 6, 2026 | SELL | 10,058 | $22.88 | $230.1K | Form 4 |
| Doyle Mittie | Chief Medical Officer | May 5, 2026 | SELL | 1,679 | $16.00 | $26.9K | Form 4 |
| Chan Mitchell | director | May 6, 2026 | SELL | 3,167 | $22.88 | $72.5K | Form 4 |
| Sullivan Christopher Ryan | Chief Financial Officer | Apr 29, 2026 | SELL | 8,458 | $13.09 | $110.7K | Form 4 |